Stem cell spe­cial­ist Ncar­dia bags new funds to help scale man­u­fac­tur­ing ops

A Bel­gian cell ther­a­py com­pa­ny has se­cured $60 mil­lion in fund­ing to strength­en its man­u­fac­tur­ing op­er­a­tions, and grow the cell and gene ther­a­py ecosys­tem across the world.

Ncar­dia land­ed the fund­ing from Kinic­i­ti, a US in­vest­ment plat­form backed by Welsh, Car­son, An­der­son & Stowe, a New York City pri­vate eq­ui­ty com­pa­ny. The move gives Kinic­i­ti a con­trol­ling stake in Ncar­dia to en­hance any­thing from dis­cov­ery to clin­i­cal pro­grams to com­mer­cial­ized pro­duc­tion, the com­pa­ny said in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.